Francis Medical concludes first commercial procedures with Vanquish system

Vanquish uses ultrasound, transurethral and electromagnetically guided thermotherapy to ablate prostate tissue.

CAPTAIN Trial Comparing Profound’s MRI-Guided TULSA Procedure™ to Robotic Radical Prostatectomy Successfully Meets Primary Safety Endpoint, Preservation of Erectile ...

First multicenter, randomized controlled trial directly comparing a new technology to robotic RP for men with localized prostate cancer to ...
Morningstar

Francis Medical Announces First Commercial Procedure with the Vanquish® Water Vapor System for Prostate Tissue Ablation

MINNEAPOLIS, Feb. 3, 2026 /PRNewswire/ -- Francis Medical, Inc., a privately-held medical device company, announced the first commercial procedure using the Vanquish Water Vapor Ablation System at ...

Scan that makes prostate cancer glow reduces need for invasive tests

A scan that makes prostate cancer cells “glow” could halve the number of men needing invasive biopsies, research suggests. The imaging test highlights aggressive prostate cancer cells, reducing the ...
Nasdaq

Growing Body of Clinical Evidence Points to the Potential of Profound Medical’s TULSA Procedure Becoming a Mainstream Treatment Modality Across the Entire Prostate Disease ...

— Clinical evidence continues to highlight TULSA’s ability to treat an unrivalled variety of patients with localized prostate cancer and/or BPH — “The various presentations made at AUA and other major ...